WHO Director-General Dr Tedros Adhanom Ghebreyesus speaking at a US press conference in Washington DC. on 7 April, after a series of recent meetings with the US Administration of Joe Biden.

A new WHO White Paper on strengthening Health Emergency Preparedness and Response supports the creation of a “Global Health Emergency Council” under WHO auspices and some “targeted amendments” to existing International Health Regulations governing emergencies.

However, the new White Paper, issued under the name of WHO Director General Dr Tedros Adhanom Ghebreyesus, also avoids taking a clear position on specific elements of reforms to the IHR rules – batting the issue back to member states.

Reform to the IHR rules, which the White Paper describes as “still too slow” to be effective in pandemics, appears to be shaping up as a key issue for debate at the upcoming World Health Assembly, which meets at the end of the month. 

The IHR reforms are seen as the most immediate answer to some of the failures of the COVID-19 pandemic – pending the negotiation and adoption of a new Pandemic treaty, convention or other legal instrument, which will take at least two years, followed by a ratification process. 

The United States is pushing for rapid adoption by the WHA of a proposal for a series of targeted IHR amendments, introducing more time-bound requirements for reporting outbreaks, and greater transparency. 

The US proposal for amended IHR rules would set tight, clear timelines for member states to report suspicious pathogen outbreaks to WHO, and for WHO to report those onwards to other member states and the public. However, it’s unlikely that China and Russia will readily agree to the US proposal – due to the threats they perceive to their sovereignty. 

United States already tabled pinpoint edits to the IHR 

(left) World Health Organization Headquarters in Geneva (right) White House in Washington, DC.

Since US President Joe Biden took office, WHO’s relationship with the US administration has vastly improved, as evidenced by Tedros’ recent trip to Washington D.C., followed by the recent breakthrough agreement to increase fixed, annual member state contributions to WHO – supported by the US.

However, the Director General still must continue to balance the relationship with Washington against the countervailing pressures of other member states.  So a proposal to streamline the IHR reform process, without endorsing specific reforms, may be the best way out for him.

Similar tensions also are evident, reading between-the-lines of the zero draft report by the WHO member state Working Group on Pandemic Preparedness and response – published just a day before the White Paper.  The Working Group report suggests that tough questions on IHR reforms could still be punted down to the autumn, at least. 

The member state draft suggests that an  IHR “Review Committee” might be set up by the WHA to consider a range of member state reform proposals – implying that beyond the United States, other nations are also in the process of drafting plans for IHR reform. The Working Group would then report back by October – with a hoped-for clear set of proposals for IHR overhaul. 

Both the WGPR and DG reports are labeled as “Zero Draft” and “Consultation Draft” respectively, indicating their wide-open nature.  Both contain a much longer laundry list of reform items, ranging from thorny questions around access and equity to more action on “One Health” and global health security, suggesting that it’ll be at least several weeks until it becomes clear what shape and direction talks take at the WHA.  

Director General text proposes “streamlined process on IHR amendments”  

The World Health Assembly meets 22-28 May in Geneva, Switzerland.

In terms of IHR reform, the Director General’s proposal for a streamlined process of creating amendments to the existing IHR says the following: 

“The inherent tension between the aim to protect health and the need to protect economies by avoiding travel and trade restrictions has been noted by the IHR Review Committee and the IPPPR [Independent Panel on Pandemic Preparedness and Review] as the most important factor limiting compliance with the IHR,” the Director General’s report notes, referring to two independent  reports on pandemic response, highly critical of WHO’s performance as well as of the IHR’s shortcomings, that were issued last year.

Adds the Director General’s White Paper:  

“In addition, too many countries still do not have sufficient public health capacities to protect their own populations, and to give timely warnings to WHO; the global alert system is still too slow; and the current self-reporting mechanism on the implementation of core capacities lacks incentives for compliance with the IHR. The absence of a Conference of the Parties for the IHR is an overarching limitation in their effective application and compliance.” 

“But to build further trust and strengthen global governance for health emergencies, amending certain articles of the IHR, while strengthening their implementation, is necessary. Such targeted amendments should make the instrument more agile and flexible and should facilitate compliance with its provisions,”

A related issue is the need to streamline the process to bring IHR amendments into force, which at present can take up to two years. Ensuring that the IHR can be efficiently and
effectively amended to accommodate evolving global health requirements is key to their continued relevance and effectiveness.

“A targeted amendment to achieve this streamlining has been proposed and is currently being discussed informally. The approval of this proposal at the 75th World Health Assembly will contribute substantially to ensuring that the IHR remains a foundational and relevant global health legal instrument.”

Working Group hedging bets 

Chinese delegate at the virtual World Health Assembly in May 2020: geopolitical tensions will likely make consensus on IHR a challenge at this year’s 2022 Assembly.

The Working Group text, meanwhile, suggests a flexible time-frame for reaching consensus on IHR reforms, stating that it: “Supports the Health Assembly continuing with an inclusive Member State-led process on amending the IHR (2005)… and proposes the following approach for adoption by the Seventy-fifth World Health Assembly”: 

“(a) Decision adopted by Seventy-fifth World Health Assembly that, in overview: – adopts any amendments to the IHR ready for adoption (if any); – agrees a Member State process to convene between the Seventy-fifth and Seventy-sixth World Health Assemblies to take forward work on all proposed IHR-targeted amendments; and – invites the Director-General to convene an IHR Review Committee to make technical recommendations on the proposed amendments referred to in subparagraph (b) below, with a view to informing the work of the Member State process. 

“(b) Proposed amendments to be submitted by 30 June, 2022. All such proposed amendments will be distributed by the Director-General to all States Parties without delay. (c) An IHR Review Committee to be established by the Director-General in accordance with Article 50(1)(a) of the IHR, with particular attention to be paid to the fulfilment of the letter and spirit of Article 51(2). 

“(d) The Member State process, to be convened no later than September 2022, should be aligned with the INB process, as both the IHR and the new instrument are expected to play central roles in pandemic PPR in the future. 

(e) The IHR Review Committee to submit its report to the Director-General by October 2022, with the Director-General transmitting it without delay to the Member State process. The Director-General will also communicate the report to the Executive Board at its 152nd session, in accordance with Article 52(3) of the IHR Independent Panel review.” 

Global Health Emergency Council under WHO leadership

Helen Clark, Co-Chair of the Independent Panel for Pandemic Preparedness and Response, which had proposed a Global Health Threats Council, under the UN General Assembly auspices.

The proposal for a Global Health Emergency Council under WHO auspices, complemented by a World Health Assembly Emergency Committee, is another key element of the Director-General’s White Paper Plan.

It’s clearly intended to head off the creation of a similar body under the UN General Assemnly Secretariat and/or G7 auspices, as had been proposed last year by The Independent Panel report and in some other fora.  

“Several panels have proposed the establishment of a high-level council on global health emergencies, comprising heads of state and other international leaders,” states the Director General’s White Paper.  

“WHO supports this concept and proposes the establishment of a Global Health Emergency Council, linked to and aligned with the constitution and governance of WHO, rather than creating a  parallel structure, which could lead to further fragmentation of the global architecture of HEPR.” 

Unlike IHR reform, the WHO White Paper clearly “puts the WHO foot down” against the creation of other additional structures outside of the Organization that have at times been proposed, one diplomatic observer told Health Policy Watch.

The WHO White Paper does, however, support the creation of a joint WHO and World Bank-managed Financial Intermediary Fund (FIF) as a standing mechanism for funding countries’ pandemic preparedness and response needs.

A number of countries, led by French and Germany, also have supported the idea of linking the funding mechanism to a new peer-review process by member states of countries’ pandemic planning, called a “Universal Health and Preparedness Review (UHPR).

The UHPR initiative is seen as a way of reinforcing the linkage between a country’s real preparedness status and its eligibility to compete for certain types of financial support.

“It’s very interesting as an idea, but not everyone wants to have this clear linkage between reforms and funds dispersed and this peer review process,” the observer said.

Overall, however, the White Paper, “is very broad, but it has the merit that it brings together the points made by the various reform panels, for a more structured discussion of what is doable or not,” the observer added.

“Clearly some proposals are more consensual that others, but at least it’s a good point of departure.”

Image Credits: WHO/P. Virot & LoC/Carol Highsmith, WHO, UNAIDS/Twitter.

Data sharing in the time of COVID-19: What works & what we need

Preparing for future pandemics requires us to reuse and share data quickly in order to repurpose that information for improved diagnostics and treatments, proposed data experts and scientists at a high-level discussion at the Geneva Health Forum Wednesday afternoon.

“It’s the value of what’s in data that can be reused, repurposed, to create new knowledge to provide insights into guidelines, and even lead towards better and improved treatments,” said Rob Terry, TDR, the Special Programme for Research and Training in Tropical Diseases.

The panel, ‘Data sharing in the time of COVID-19: What works and what we need’, focused on raising awareness of the lack of sharing of de-identified individual level data from COVID-19 clinical studies to sharing and identifying strategies for sharing data during the pandemic.  

All panelists noted that with sharing data globally, privacy and confidentiality still remains a concern, with many pointing to a need for data protection alongside data sharing.

“There’s a strong need to rationalize data protection laws and then contextualize them and make sure they’re not working against the public that they’re meant to be protecting,” said Naomi Waithira, Mahidol Oxford Research Unit Data Sharing Working Group, COVID-19 Clinical Research Coalition.

Three E’s of data sharing 

Rob Terry
TDR, the Special Programme for Research and Training in Tropical Diseases

In an effort to maximize the benefits of reusing data, Terry brought up the three E’s of data sharing: efficient, ethical, and equitable.

“We must be equitable about sharing – when data is shared, it must not disadvantage those who are sharing the data,” Terry said.

He points to how researchers from low- and middle-income countries often find themselves exploited and exported for the benefit of others.

Data sharing also needs to be fair, so that it’s findable, accessible, and able to be used with other data sets. 

While there are hurdles to overcome with data sharing, shifting to a culture where data sharing is the norm is key, said Terry. 

“There are a lot of issues with data sharing, and they tend to be political, ethnical, technical, legal, and social. And we have solutions for many of those.”

“We need to create a culture where sharing is the norm. The benefits we’re gaining are so much better when the data is available and available for reuse rather than locked away in a drawer or in these days, a hard drive.”

‘Blanket’ privacy laws do more harm for data reuse 

Naomi Waithira
Mahidol Oxford Research Unit
Data Sharing Working Group, COVID-19 Clinical Research Coalition

However, while data privacy laws exist worldwide, to enable data sharing for scientific research, there needs to be more than just “blanket privacy regulation’, but rather regulation that addresses the actual risks of disclosure within its details,” Waithira proposed. 

In the past, there has been the General Data Protection Regulation (GDPR) in the European Union, the Protection of Personal Information Act in South Africa, the Personal Information Protection Law in China, and others that aim to ensure responsible data collection. 

 With data anonymization and de-identification from these laws used as ways to address confidentiality, this reduces the scientific usefulness of the data that could be used for datasets in the future. 

“When anonymizing data, you remove parameters which could potentially identify the person, but the complexity of data reuse [needs this information] because we actually do not know what in the future these datasets could be used for.” 

“We need to understand the data protection rules. What exactly is meant by the GDPR, what does it cover, what doesn’t it cover?” added Nathalie Strub-Wourgaft, of COVID-19 Response & Pandemic Preparedness, Drugs for Neglected Diseases initiative (DNDi). 

Waithira brings up a need to engage with the public so they fully understand their needs and what is actually considered risks with data sharing. 

“We need to have more engagement with the public to understand their concerns and what they perceive as risks over data sharing and reuse, and then use that data to rationalize data protection laws,” she said.  

Harmonizing and pooling data during times of peace 

Nathalie Strub-Wourgaft
COVID-19 Response & Pandemic Preparedness, Drugs for Neglected Diseases initiative

Others addressed how data must be pooled and harmonized across the board in order to quickly combat future pandemics and the spread of  infectious diseases. 

“We need to have information quickly to make sense of the data as quickly as we can,” said Strub-Wourgaft.

Pooling data together, stated Strub-Wourgaft, allows for secondary research to take place, which is especially important for neglected tropical diseases (NTDs).

NTDs typically have little research, few guidelines and little data to work with. 

Using sleeping sickness as an example, DNDi’s consideration of data from diverse studies together allowed regulators to define a certain drug for treatment of sleeping sickness as a benchmark, she said. This also paved the way for other treatments to be developed and to further understand the severity of the illness.

“How do you make sense of clinical severity symptoms in relation to white blood count? You cannot do that without having more coherence by looking at all the data, putting them together and making a robust analysis,” she pointed out.  

Pooling data also provides researchers with more robust indicators about specific sub-population responses, as well as defining factors like: safety signals to consider in  treatment and baseline characteristics to predict severity progression of an illness, as has been the  case with COVID-19. 

Philippe Guérin
Infectious Diseases Data Observatory

Had this harmonization occurred before, we would have prevented many missed opportunities on the potential therapeutics of certain drugs, added Philippe Guerin of the Infectious Diseases Data Observatory.  

The infectious Diseases Data Observation (IDDO) is a platform managed by University of Oxford which is providing researchers with a quality-assured means of sharing data with other experts exploring the same disease or treatment – it’s the kind of platform that Guerin and other panelists say should be expanded now in preparation for the next pandemic – to enable more robust studies of treatments more rapidly. 

“We can’t organize things in times of crisis,”  Guerin said. “Things have to be organized and set up in times of peace. Without this organization in place, we will eventually fail again as we did for Ebola, as we did for COVID. We will fail again to have an environment where we can share and amalgamate data of value for a pandemic like COVID.” 

Existing data repositories such as IDDO were previously recommended as a way to support data sharing effectively, ethically, and equitably. (See related Health Policy Watch story)

Image Credits: Internet Archive Book Image/Flickr, GHF.

The South Sudan Minster of Health, Elizabeth Chuei, is receiving the COVID-19 vaccine at Juba Teaching Hospital.

Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives.

This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which COVAX is the central pillar, on Thursday.

Ted Chaiban, head of COVID Vaccine Country Readiness at the COVID-19 Vaccine Delivery Partnership, said that COVID-19 vaccination drives provided an opportunity to strengthen “pre-existing health challenges”, particularly cold chain delivery, health management information systems and training health workers. 

“Integrating COVID-19 vaccination into primary healthcare activities such as measles, polio, and the distribution of malaria bed nets has become important,” said Chaiban.

In January, 34 countries had vaccinated less than 10% of their populations, but this was down to 18 – and 15 of these were in conflict areas.

“In everything we do, what’s important is to put countries’ governments and partners at the centre,” added Chaiban.

“The next three to four months are key as countries use campaign-style strategies to accelerate COVID-19 vaccination while also addressing some of these other health priorities they are grappling with.”

Ted Chaiban, Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery, COVID-19 Vaccine Delivery Partnership

COVAX’s vaccine delivery partners, Gavi and UNICEF, helped Burkina Faso with funds to run a rapid vaccination campaign as there was a risk that 100,000 of its Pfizer doses would expire.

“As we speak, there is a campaign on the way in DR Congo to use several hundreds of thousands of doses of vaccine that expire between May and July,” said Chaiban.

However, Gavi CEO Seth Berkley said that the waste of vaccines was well below 10%. 

The demand for vaccines from COVAX in the second and third quarters of the year is around 380 million doses. But last December alone, UNICEF delivered more than 350 million doses on COVAX’s behalf. 

“Both delivery shipments and demand are slowing down, specifically from quarter one to two,” said Eva Kadilli, director of UNICEF’s supply division.

“While there is ample supply of vaccines to satisfy country needs, massive work has also been done to support the overall infrastructure to enable the uptake of vaccines and really turn them to vaccination as we speak,” said Kadilli.

This includes the delivery of over 1.3 billion syringes – both to address COVID-19 surges and to ensure that routine immunisation doesn’t suffer. 

Rosemary Mburu

Rosemary Mburu, Executive Director of WACI Health and Co-Lead of the ACT-A’s civil society platform, said that vaccine hesitancy and a general distrust of science needed to be addressed.

“Even as supply picked up, we still have pockets of hesitancy and really low confidence in science itself,” said Mburu, adding that Omicron had lowered people’s risk perception.

“During the peak, there was a lot of diversion of human resources from different programmes to come in support COVID-19 response, and now with fewer cases, those health care professionals have returned to their usual line of duty, so you find that we don’t necessarily even have enough vaccinators, for example,” she added.

Berkeley stressed that COVAX did not ship any doses unless countries wanted them – and “we try to give countries their first choice of vaccine, and if that is not available, then obviously offering a second choice as well”. 

However, Gavi skirted questions about whether it would buy Johnson and Johnson (J&J) vaccines produced by South African generic company Aspen, following weeks of appeals from the Africa Centre for Disease Control. Aspen is likely to close its J&J production facility as it has yet to receive any orders for its vaccines despite 

Berkley simply said there was “more demand for mRNA vaccines”. However, he added that COVAX was “committed to making all vaccines available that are in the portfolio that meet WHO quality standards and recommendations”.

“The challenge we have is that some companies are going to try to particularly push their vaccines,” he added.

Previously, a Gavi spokesperson told Health Policy Watch  that “COVAX is committed to diversifying global supply, including through the development of regional manufacturing sites, especially in Africa.

“In the case of Aspen, the current overall demand situation means we are currently not in a position to buy large quantities of vaccines. However, we are in discussion to see if a collaboration would be feasible as part of expanding regional supply.”

Image Credits: UNICEF.

Geneva Health Forum panel tackles “the effects of pollution on health: Current risk and possible solutions” on May 5, 2022.
Geneva Health Forum panel tackles “the effects of pollution on health: Current risk and possible solutions” on May 5, 2022.

Pollution is responsible for the premature deaths of approximately 9 million people each year; more than the number of deaths attributable to war and terrorism, malaria, AIDS, tuberculosis, drugs, alcohol or even smoking.

Chemical pollution severely undercounted in premature deaths from pollution

That’s also the equivalent of one in six premature deaths worldwide, pointed out Rachael Kupka, of the Global Alliance on Health and Pollution (GAHP) at a panel on the effects of pollution on health on Thursday, the final day of the Geneva Health Forum.

That estimate, originally published in 2017 by the Lancet Commission on Pollution and Health, is likely even higher now, insofar as an updated Lancet report is expected to be published on May 18, she noted.

While the conference this year has focused heavily on a emerging knowledge about the complex relationship between climate change, biodiversity loss, and pandemic risks – the panel on the GHF’s closing day, drove home the point that pollution of the air, waterways and soils is a fundamental driver of all of these trends. And despite half a century of environmental action, health risks from pollution remain as acute as ever.

Types of pollution

Types of pollution

Lead poisoning – one in three children worldwide have elevated blood lead levels

Lead pollution in the Amazons

While there are many sources of pollution – from traditional ones such as biomass burning and water contamination to ‘modern’ sources like vehicles, one important risk that still needs more attention is lead pollution, Kupka and other panelists pointed out.

Despite the worldwide phase out in leaded gasoline, environmental lead remains pervasive, causing some 900,000 deaths a year, according to the 2017 Lancet report.

“We have not eradicated lead poisoning,” stressed Kupka , citing a recent report by UNICEF and Pure Earth that showed one in three children have elevated lead levels of at least 5 micrograms per decilitre of blood – the level at which the World Health Organization recommends intervention. That’s 800 million children and 90% of them live in low-and-middle-income countries, often least equipped to handle the health impacts.

“Lead poisoning causes irreversible neurological damage,” Kupka said.

It also caused up to a 2% drain on LMIC’s Gross Domestic Product (GDP) from loss of productivity, and accounts for 7% of healthcare costs in middle incomes countries.

According to Kupka, primary sources of lead exposure today are not always the expected ones.

They include spices, cookware and lead acid car and truck batteries – as well as areas tainted by oil extraction and other industries.

She explained that in some countries, especially in South Asia, Eastern Europe, the Middle East and North Africa, lead salts are added to spices like turmeric and paprika to make them more colourful.

“Due to climate change, sometimes the turmeric roots become a dull yellow. People use turmeric for colouring – they want to make their rice and other foods colourful – so they are adulterating the spice,” Kupka said.

In countries ranging from Mexico, Turkey and Morocco some artisans still glaze their ceramic cookware with lead glazes.

And in most of the developing world, lead acid batteries are not properly disposed of, but rather dropped into landfills; lead and sulphuric acid seep into the soil contaminating the earth and underground fresh water supplies.

The effects of lead poisoning can be seen in the Peruvian Amazon, where oil extraction started mainly in indigenous areas in the 1960s, according to Cristina O’Callaghan.
The effects of lead poisoning can be seen in the Peruvian Amazon, where oil extraction started mainly in indigenous areas in the 1960s, according to Cristina O’Callaghan.

The effects are acute and chronic

Extractive industries, such as oil, are another source of lead poisoning, including for communities living around mining sites, where the gradual contamination of land and waterways may receive little notice or attention.

The Peruvian Amazon is one example, said another panelist, Cristina O’Callaghan of the Universitat Oberta de Catalunya and Barcelona Institute for Global Health.  Oil extraction began there in the 1960s. In recent years, she lead research efforts looking at the health effects of exposure on the area’s indigenous residents to lead, present in the crude oil spills that dot the areas forests and waterways – also contaminating local wildlife.

A 2021 study of some 1047 people in 39 indigenous communities of the northern Peruvian Amazon found that 49% of children and 60% of adults had blood lead levels (BLLs) above the WHO Guideline of 5 micrograms per decilitre of blood. The study, published in Environment International, found mean blood levels in some areas as high as 8.1 µg/dL among children under the age of 12, and 8.8 µg/dL among older participants.

Mean blood lead levels (BLL) in the study population was higher than 5 μg/dL
49% of children and 60% of adults had BLL above this threshold

“There are several routes of exposure: skin absorption and inhalation, but also ingestion,” O’Callaghan said, citing another study that observed that 50% of hunted biomass in the area had been affected by oil pollution. Displaying images of animals with faces covered in oil, she described how animals often seek out oil slicks to lick up the salts that their bodies require – but in this case are toxic lead salts.

“It turned out consumption of wild game was also a factor,” she said. “From the animals, it was getting into humans.”

Health effects are both acute and long-term. One cross-sectional study published in 2016 by BMC that looked at communities living around oil fields in the Ecuadorian and Peruvian Amazon, as well as the Nigeria’s contaminated Delta region, catalogued health effects as ranging from respiratory, eye and skin symptoms, headache, nausea, dizziness and fatigue, to neurological and psychological disorders; reduction of lung function, genotoxicity and alterations in hormonal status.

“It is very important to have valid data on environmental exposures and conditions of life of understudied populations,” she continued. At the same time, since there is already overwhelming data about the health effects of lead, even at very low levels of exposure, “we should not wait. We do not need these complex studies to act.”

Air pollution in Mashhad, Iran

More than six million people die each year from air pollution

Pollution is the largest cause of death globally.

Even more pervasive than lead, is air pollution from ambient air and household air pollution sources – which accounts for some 7 million deaths annually, according to the World Health Organization’s latest report.

“It is estimated that 99% of the entire world’s population breathes air with unhealthy levels of fine particulate matter (PM2.5) and nitrogen dioxide (NO2)that threatens their health,” said Liz Arnanz Daugan of the NCD Alliance.

Daugan said that air pollution ranks up with unhealthy diets, physical inactivity and tobacco use as a leading but modifiable cause of noncommunicable disease.

While many people associate air pollution with respiratory diseases and lung cancer, air pollution at low levels of chronic exposures also is responsible for a significant proportion of deaths globally from heart disease, hypertension and cancers as well as having impacts on almost every other organ of the body somehow.

People are exposed to higher levels of air pollutants in Asia, Africa and the Middle East in their homes and on the streets – and they may also be exposed to higher levels of dust and chemical air pollutants in workplaces, particularly informal workplaces where enforcement of occupational health rules is poor or non-existent.

The case of Madagascar

Health impacts of pollution in Madagascar

Madagascar is a country whose air quality is considered “moderately unsafe,” according to WHO standards. Some 28,280 people died as a result of air pollution in the country in 2016, according to Tatiana Eddie Razafindravao, chargé d’affaires of the country’s UN Mission to Geneva and the UN, who also spoke during the GHF session.

Considering all forms of air, water and chemical pollution together, some 31% of all premature deaths in Madagascar are due to pollution, shared Razafindravao during the session, citing data from 2016. “That’s a loss of 3.3 million healthy life years in 2016 through exposure to pollution.”

The air pollution in Madagascar is a result mainly of emissions from vehicles, bushfires, brick making, use of fossil fuels, charcoal consumption and waste that is incinerated in urban spaces.

A few years ago, with the support of GAHP, the country decided to take action.

In 2018, it ratified a “Health and Pollution Action Plan” and established a pollution control taskforce. The Health and Environmental ministries started evaluating their pollution policies and made a national plan for health security and air pollution control.

“But we are not without challenges,” said Razafindravao, noting that the country lacks technical and financial support to move as quickly as it wants to against pollution. It is also sometimes difficult to convince the public to adopt new behaviours that are conducive to preserving the environment and protecting their health, she said.

“We are working on developing a 10-year roadmap for pollution management in collaboration with GAHP,” Razafindravao explained.

She said Madagascar also hoped to establish an independent institute for pollution and chemical management that will bring together state entities, academicians, the private sectors, NGOs and international organizations around solving the crisis.

But she added that national and international legal frameworks are also important – because those in turn compel more investments and enforcement.

Practical steps

Daugan called on countries to adopt, and more strictly enforce, tougher emission standards for key pollutants.  Those should include air quality standards that correspond to WHO guideline levels for PM2.5 and NO2.

More sustainable urban planning, particularly in cleaner transport systems can also make physical activity more feasible – for a double “co-benefit” to health.

Other measures include the removal of fossil fuel subsidies that amount to hundreds of billions of dollars a year in G-20 countries alone – and wreak trillions of dollars in health damage, she said.

Removal of such subsidies also would clear the way for redirecting more development investments toward health-promoting renewable energy; cleaner public transport, walking and cycling; and improved housing with access to clean energy sources.

“We must make addressing pollution a national and international priority,” Kupka concluded.

Image Credits: ISGlobal – Barcelona Institute of Global Health , Maayan Hoffman, GAHP , Screenshot of PowerPoint presented by Rachael Kupka on May 5, 2022 at the Geneva Health Forum, Screenshot, PowerPoint Slide, Cristina O’Callaghan on May 5, 2022, O'Callaghan-Gordo, C, et al. Environment International 2021, Mohammad Hossein Taaghi, GAHP.

Geneva Health Forum’s Global Health Lab showcased over 100 new diagnostics and treatment tools designed for resource-constrained settings. GICMED is one of the over 100 innovations and devices that were featured. These innovations are specifically suited for resource-limited settings in lower-income countries.

Dr Tankou Conrad — Founder, GICMED
Dr Tankou Conrad — Founder, GICMED

While global attention continues to be on the COVID-19 pandemic and outbreaks of other infectious diseases, Africa’s burgeoning cancer epidemic continues to rage on, and smart technologies are being considered as tools to potentially tackle the epidemic and bring respite to patients – especially women.

In Cameroon, available data showed about 6,000 women died of cancer in 2018, and according Professor Paul Ndom, president of Cameroon’s National Committee for Cancer Prevention, the risk of contracting COVID-19 in the hospitals has also discouraged many patients with cancer from coming to receive care in the clinics thus potentially worsening the cancer outlook in Cameroon.

Global Innovation and Creative Space (GIC Space), through its flagship product GICMED, hopes to reduce breast and cervical cancer death rates in Cameroon and, by extension, Africa’s underserved communities and rural settings that generally lack access to cancer care services.

Its founder, Dr Tankou Conrad told Health Policy Watch on the sidelines of the Geneva Health Forum that cancer care in Cameroon is negatively impacted by lack of access, a paucity of medical professionals that can screen for cancers and lack of cancer screening equipment.

The medical doctor-turned-technology-enthusiast said the innovation was inspired by his experience as a frontline healthcare practitioner in Cameroon’s rural community. 

“I had to witness, first hand, the challenges women face in accessing specialized breast and cervical cancer healthcare. This is the motivating factor behind it. Creating a solution that can be scaled anywhere so that every woman can access breast and cervical care is really what we are motivated to work on,” he said.

The GICMED approach

Conrad described GICMED as an innovative technology that specifically adapts to Sub-Saharan Africa and can work in rural settings such that every woman, irrespective of her location or status, can get screened and diagnosed within the community where she lives.

The GICMED bouquet of solutions includes a smart digital microscopy system, smart speculum, simple biopsy device, telemedicine platform and an e-training platform.

“They enable the medical data required by a specialist to be captured at the point-of-care by on-site nurses who are trained and are now sent to the medical specialist who can be found anywhere in the world. The specialist can make the diagnosis remotely and the woman can be planned for care thereafter,” he said.

The made-in-Cameroon solution is regarded as putting into context the adaptability for the targeted region. Conrad also revealed that pilots for the solutions have been conducted in Cameroon.

“The feedback has been very impressive because we have been able to bring to light, in an evidence-based manner, that using adapted technologies can enable women to get screened and diagnosed at the point-of-care even in the most remote settings.”

For the smart speculum technology, he said it also has a dual application of also serving as a colposcope. This means that “it is portable, easy-to-use and is about 100 times cheaper than what is obtained in developed countries”.

The innovation has been recognized by the Next Einstein Forum, Total Startupper program, and  was a finalist at the 2021 CISCO Global Problem Solver Challenge, among many other awards and recognitions. Dr Tankou was previously on the Quartz Africa Innovators top 30 list of pioneers.

Image Credits: Paul Adepoju.

  Excess deaths during the first two years of the COVID-19 pandemic are almost triple officially-reported deaths – around 14.9 million deaths rather than the 5.4 million currently reported, according to new figures released by the World Health Organization (WHO).

These much-delayed excess death statistics were finally released on Thursday after being contested by India, which appears to have massively under-estimated its mortality between January 2020 and December 2021.

The Indian government had reported 481,000 deaths in the two-year period whereas the WHO expert panel pegged India’s deaths as almost 10 times higher – at 4.75 million – WHO’s data technical officer, Dr William Msemburi, told a media briefing.

Ten countries are responsible for 68% of all deaths, namely Brazil, Egypt, India, Indonesia, Mexico, Peru, Russia, South Africa, Turkey and the US (alphabetical order), added Msemburi.

More men (57%) than women (43%) died, while 82% of those who died were over the age of 60, he added.

Direct and indirect deaths

Dr William Msemburi, WHO Technical Officer, Department of Data and Analytics

Excess mortality is the difference between the number of deaths that have occurred and the number that would be expected in the absence of the pandemic based on data from earlier years.

Explaining the “excess deaths” over the past two years, WHO’s Dr Samira Asma said that they included deaths caused directly by COVID-19 and deaths indirectly associated with the pandemic due to unmet health needs.

Meanwhile, 70 countries did not have accurate measures of their population’s mortality, 42 of these in Africa, and figures for these countries were reached purely by modelling.

“This is a staggering toll, and there are staggering data gaps,” said Asma, WHO’s Assistant Director-General for Data and Analytics.

Dr Samira Asma, WHO Assistant Director-General, Data, Analytics

WHO Director-General Dr Tedros Adhanom Ghebreyesus, said that the “sobering data not only point to the impact of the pandemic but also to the need for all countries to invest in more resilient health systems that can sustain essential health services during crises, including stronger health information systems”.

“WHO is committed to working with all countries to strengthen their health information systems to generate better data for better decisions and better outcomes,” added Tedros.

Dr Jeremy Farrar, Director of Wellcome, said that “this devastating death toll was not inevitable”.

“Even now a third of the world’s population remains unvaccinated,” added Farrar. “More must be done to protect people from the ongoing Covid-19 pandemic and shield humanity against future risks.

“Climate change, shifting patterns of animal and human interaction, urbanisation and increasing travel and trade are creating more opportunities for new and dangerous infectious disease risks to emerge, amplify and then spread.”

The WHO and the United Nations Department of Social, Economic and Social Affairs worked together on the data, guided by a technical advisory group of 40 global experts.

“Underlying this process is WHO’s commitment to producing a completely transparent audit trail of all these estimates that we put out,” said WHO senior data advisor Dr Somnath Chatterji.

“This means that we make available all the input data, the method that we have used to generate these estimates as well as the code that has been used. If a country would like to look at this estimate they can, first of all, understand the entire process. Then they can take their own input data if needed, and rerun these models to generate their estimates.”

Mechanical ventilators can help patients with severe COVID-19 breathe.

The COVID-19 pandemic has increased the level of worldwide investment in respiratory care and now that cases are on the decline, countries need to develop long-term strategies to use oxygen, according to health experts.

“Severe pneumonia, sepsis, trauma complications – there are many patients that would benefit from oxygen,” explained Janet Diaz, a team lead at the World Health Organization (WHO) who spoke about oxygen redeployment on Thursday morning at the Geneva Health Forum.

Every year, 7.2 million newborns in low-and-middle-income countries (LMICs) suffer from severe pneumonia and need medical oxygen to survive. To date, fewer than one in five children actually gets it, making pneumonia the biggest infectious killer of these children.

“It is always important to think about where patients get oxygen – emergency departments, critical care areas, acute care areas – and the different populations of patients that could be oxygen candidates,” Diaz continued. “The investments made are a big win. Now we have to ask, ‘what’s next?’”

Diaz stressed that oxygen redeployment “won’t just happen.” Specific plans to integrate COVID-19 equipment into the health system will be required for the transition. She cited the first steps of this plan as creating a roadmap, entering high-level national planning with donors and engaging and training the workforce to build their capacity to properly administer oxygen to the right people at the right time.

The ACT-A Oxygen Emergency Task Force

The ACT-A Oxygen Emergency Task Force was established by UNITAID in February 2021, about a year into the pandemic, to help LMICs gain access to secure oxygen supplies and the technical support and skills to manage them – and is expected to continue to play a key role in the transition.

More than 20 United Nations and global health agencies partnered on the task force, mobilising more than $700 million in grant financing in the first year. In December 2021, the US government announced plans to infuse another $75 million for additional support of USAID’s Rapid Response efforts, which includes investment to help strengthen oxygen market systems from production to delivery.

The task force was initially focused on five key objectives, which were outlined by a UNITAID representative on Thursday: assessment of acute and long-term oxygen needs in LMICs; support and review of funding requests to the task force; procuring oxygen; increasing LMIC access to liquid oxygen, oxygen plant repairs and critical parts; and strengthening advocacy and communication efforts to highlight the importance of oxygen.

Towards the end of the first year, the task force shifted slightly to focus on identifying priority countries; coordinating action on quick wins with a special focus on monitoring pressure swing adsorption (PSA) plant repairs; and resolving supply gaps and bottlenecks.

Now, as a result of this work, many LMICs have started this year with a greater capacity to meet the needs of their citizens – those with COVID-19 and others who are suffering from respiratory diseases, the representative said.

Nigerian physician Adamu Isah speaks via video at the Geneva Health Forum on May 5, 2022.
Nigerian physician Adamu Isah speaks via video at the Geneva Health Forum on May 5, 2022.

Nigeria: Six lessons learned

Adamu Isah, a Nigerian physician who works with the country’s Save the Children program, highlighted the lessons that his country learned over the past two-and-a-half years, which he said could be translated to other LMICs.

Nigeria is a federal republic with state governments that have their own autonomous parliaments.

“When you run a program, you have to take note of this and make sure there is coordination between the national efforts and those on the state and local level or it will not be sustainable,” Isah stressed.

Nigeria’s Health Ministry established an oxygen desk where regular meetings between all engagement parties to share ideas. Now, the country is preparing to conduct a nationwide assessment to harmonize the assessments done by individual partners.

He also said Nigeria was evaluating how to ensure it could sustain its oxygen supply.

The current policy is that, for the first six months that people need oxygen in Nigeria, they receive it free of charge. But this was becoming unsustainable – the lesson being that programs need to be evaluated for their sustainability from the beginning. He said the country is now considering either looking for alternative and supplementary funding sources or asking patients to pay for some of the cost.

They also learned to document the oxygen being given to patients.

“Before COVID, no one was talking about oxygen in hospitals,” Isah said, but they quickly learned the need to document the type and amount of oxygen being given, and for what indication it was being used, to ensure proper use and also anticipate future needs.

Nigeria also understood that some people may be hesitant to give their children oxygen and therefore learned to engage religious leaders and traditional rules to promote its use.

Lastly, the country has begun to evaluate if it is better to procure oxygen devices or to develop the capability of manufacturing them in-house.

“In the days of COVID there were long delays,” Isah said. “The question is could we make our own?”

Rahel Belete says there needs to be international cooperation around oxygen. She spoke at the Geneva Health Forum on May 5, 2022.
Rahel Belete says there needs to be international cooperation around oxygen. She spoke at the Geneva Health Forum on May 5, 2022.

Ethiopia: A head start

When COVID struck, Ethiopia was in a better place than most LMICs due to work it had been doing since 2015 in collaboration with the Clinton Health Access Initiative (CHAI) to improve oxygen services at public hospitals, explained Rahel Belete, who runs CHAI’s Ethiopian program.

The country had already developed new policies and guidelines, procured more oxygen equipment and trained health workers to better diagnose and treat hypoxemia. By 2019, oxygen was available in 100% and pulse oximeters in 96% of in-patient pediatric departments where the program ran. Clinical practice had also improved.

Certainly, the investments the country made gave Ethiopia a head start, Belete said. However, the demand for oxygen during the pandemic far exceeded Ethiopia’s capacity, especially given the country had the fourth highest COVID-19 caseload in Africa.

There have been 470,647 infections and 7,510 coronavirus-related deaths reported in Ethiopia since the start of the pandemic, according to Reuters. Today, Ethiopia is only reporting an average of 22 new daily infections.

The pandemic propelled CHAI to look forward and consider a next phase of its oxygen roadmap, Belete explained.

The components of the new roadmap are focused on:

1. boosting the capacity of existing oxygen plants;

2. tracking and more effectively using data to inform decisions;

3. training healthcare workers to adopt standardized oxygen therapies, while at the same time ensuring staff knows how to use the systems and therapies that do exist so that they don’t end up in the junkyard;

4. making sure any new oxygen tools are standardized to make it easier to find and fund replacement parts, as well as putting a reliable maintenance program in palace;

5 sustainability – making sure the funding is in place to continue growing the program.

“It is important that we have a platform in which there can be international cohesion in the thinking, brainstorming and coordination,” she concluded.

Image Credits: Sky News, Agência Brasília , Maayan Hoffman.

Francoise Vanni, Director of External Relations at The Global Fund

The Global Fund intends to further prioritise integrated health systems and boost people-centred approaches, it was announced at the Geneva Health Forum on Wednesday.

Although urgent improvements in health and community systems only made up about 14% of its $3.4 billion COVID-19 budget, the organisation expressed strong commitment to these themes in future. 

New priorities emerge 

According to the World Health Organization (WHO), “integrated health systems” is a humanistic method of organising and managing health services that focuses on delivering to people the care that they need, in ways that are prompt, effective, user-friendly, and cost-effective.

Speaking at the Geneva Health Forum on Wednesday, Francoise Vanni, Director of External Relations at The Global Fund, noted that this new strategy reinforces The Global Fund’s mission, as the needs of people take centre-stage more than ever. 

“We will be focusing and incorporating this on things like supply chains, digital health information systems, digital health, community health workers and other key areas of health systems,” Vanni said.

She noted that integrated health systems have become necessary considering the growing challenges in accessing healthcare and burgeoning health issues affecting the population. 

Change necessitated by COVID-19

The COVID-19 pandemic has proven a major eye-opener for the global health financing landscape, setting new standards and models for successful programme implementation. 

It is therefore no wonder that the Global Fund, one of the largest global health financing and partnership organisations, has shifted its focus to integrated health systems  as part of its aim to invest additional resources in fighting epidemics. 

To date, the Fund’s COVID-19 Response Mechanism (C19RM) has supported countries to mitigate the impact of the pandemic on more routine HIV, TB and malaria programmes. It is largely because of its partnerships with communities and local stakeholders, Vanni says, that The Global Fund was able to respond so quickly to the COVID-19 pandemic. “These frontline responders were key”, she added, and were part of the inspiration to reboot the organisation’s future priorities.

Increasing preparation and prevention budgets

Out of The Global Fund’s Total COVID-19 approved 2021 funding of nearly $3.4 billion, nearly $472 million was spent on urgent improvements in health and community systems. This represented less than 14% of the total amount but Vanni revealed this would significantly improve in preparation for future pandemics.

 

 

 

Vaccinating dogs against rabies prevents the disease in people.

As many neglected tropical diseases (NTDs) spread via vectors like ticks or domestic mammals, human-centric prevention programmes alone are inadequate – and adopting more holistic approaches such as the routine vaccination of animals is logical. 

This was the key message conveyed by health and policy experts at a panel discussion, “For a new approach to NTDs based on One Health”, at the Geneva Health Forum on Wednesday. 

‘One Health’ is a perspective that acknowledges the interconnectedness of human health with animals, microorganisms and the wider environment. A solution aiming at more lasting, sustainable health development, it moves beyond treating disease in humans to tackle the root causes of the spread of diseases.

Dirk Engels, former NTD director at the World Health Organization (WHO)  and a member of the Swiss Alliance Against Neglected Tropical Diseases (SANTD), highlighted the potential of One Health approaches to eradicate diseases in animal reservoirs, reduce the population growth of infected animals, and consequently save more human lives.

Rabies, with its high mortality rate of 80% and explicit animal-to-human transmission, is particularly amenable to holistic control methods. As the WHO’s Bernadette Abela-Ridder remarked, rabies control is often restricted to post-exposure prophylaxis in humans, despite the potential of mass vaccination in dogs to curb rabies deaths quickly, cheaply and effectively – as 99% of rabies cases are dog-mediated.

“We know vaccinating dogs prevents rabies,” she said – yet outside the South American continent, where several countries have successfully brought down rabies deaths through mass dog vaccination campaigns, “nobody actually does it”.

“If you want to stop rabies in humans very quickly, you vaccinate the dogs,” she added. “Dogs are part of the patchwork of our society, yet nobody is responsible for them: who will take care of dogs and pay for costs of vaccination?”

Not only would this One Health-inspired strategy address the root cause of the disease, it would also circumvent the hassles of current human prophylaxis, which involves a combined multi-dose treatment administered over two weeks.  

NTDs are a group of 20 preventable and treatable diseases that disproportionately affect marginalized populations in Africa, Latin America, and Asia

Developing ‘bite-sized’ strategies 

For novel strategies against NTDs to persist, countries need to buy into the value of the approach. Indeed, a barrier to embracing One Health is its breadth, noted Abela-Ridder, being a concept that encompasses virtually any component of our environment. This can understandably feel overwhelming for governments. 

However, segmenting such preventive strategies into “bite-sized” pieces will make them far more manageable to implement. In the case of rabies control, for example, this might look like identifying one high-priority target vector, and one single intervention mode – that is, dogs and vaccination. 

This, together with strong and motivated leadership at the national level, is the key for holistic approaches to function as effectively and sustainably as possible. Encouragingly, some countries have already set up dedicated supra-ministerial units for cross-cutting action on One Health. 

For successful provincial, district and community level implementation, the best place to start is building on existing intersectoral collaboration. To achieve this, José María Gutiérrez, a One Health expert at the University of Costa Rica, raised the importance of cooperating with local administrators and parliamentarians on novel NTD prevention. They “have the key” to the intersectoral resources that will cement local programmes, even if the changes start by being “small, but incremental”. 

Galvanising the private sector 

Meanwhile, in another GHF session on One Health, speakers acknowledged that the private sector could play an important role in operationalising this approach.

The speakers stressed that, in a resource-constrained world, every sector intersects with another in a web rather than a linear value chain – and more companies are starting to understand this inter-dependency.

Uta Jungermann of the World Business Council For Sustainable Development said one of the entry points for private sector involvement was in improving health systems: “There’s a question of how to exchange the know-how, innovative capabilities, stakeholder networks, and what unique expertise businesses can bring to the table and identifying health system resilience gaps and then developing strategies to close them,” she said. 

Ilona Kickbusch of the WHO Council on the Economics of Health for All, called for the private sector to be “activated”.

“I think there are good opportunities,” said Kickbusch. “There are so-called CEO roundtables. There are pharmaceutical associations. But they talk among themselves. And then here we talk a bit among ourselves. So this dialogue needs to happen and I know that the World Economic Forum is doing a great job in bringing this together, but we need more, especially for the One Health concept”.

* Additional reporting by Shadi Khan Saif.

Image Credits: Daniel Stewart, Our World in Data.

Drug overuse in livestock is driving antimicrobial resistance. The main hotspots are in Asia, with Africa’s use of antibiotics far behind.

Animals, not humans are the largest consumers of antimicrobial drugs – and thus the leading factor driving antimicrobial resistance. But WHO and other UN actors are still dancing around the ‘cattle, chickens and pigs’ in the room. And member states aren’t keen to track animal antibiotic use trends – even at the cost of future health risks.     

More than 73% of all antimicrobial drugs sold in the world are used in animals. And mores than human uses, the booming veterinary drug market is most probably the leading factor in growing antimicrobial resistance that is rendering common antibiotics and antiviral agents progressively more useless – also driving pandemic risks.

Even so, there is no systematic global tracking of drugs sold and used on animals as well as humans by the three big UN and multilateral organizations responsible, including the World Organization for Animal Health (OIE), the World Health Organization (WHO) and the Food and Agriculture Organization (FAO).  And despite pledges to tackle pandemic risks and AMR together, it’s unlikely such surveillance will begin anytime soon. 

Thomas Van Boeckel, of Zurich ETH, explains how soaring animal consumption of antibiotics, and human consumption of industrial meat, are the leading factors driving AMR

Meanwhile, around the world, veterinarians are making huge profits from selling animal drugs to farmers and thus driving their swelling use – particularly in India, China and other parts of Asia, said Thomas Van Boeckel of ETH Zurich at a seminar on Achieving Sustainable Antibiotic Access using a One Health Approach, at the Geneva Health Forum, on Tuesday. 

“In 2017, about three quarters of all the antibiotics that we sold on this planet were used in animals, mostly to help them grow faster and to prevent infection,” Van Boeckel said. 

“So in the context of development, if you see the emergence of new resistant genes, it’s like playing the lottery and losing, well, you have more chances to lose the [AMR] lottery in animals. And once they’re there [drug resistant microbes] they can eventually result in untreatable infections in humans if they’re transmitted.” 

LMIC livestock – the ticking AMR time bomb no one is tracking

Mapping of AMR hotspots

Van Boeckel and his interdisciplinary team, comprised of food scientists, ecologists, pharmacists and veterinarians, as well as disease modelers and epidemiologists from Brazil, China, and India as well as Europe and the United States, have mapped hundreds of studies to come up with an initial ‘heat map’ of the world’s AMR hotspots. They are constantly developing that knowledge base on an open data site, Resistancebank.org.  

The group’s findings combine exhaustive data from animal drug sales, with reference to over 100 different types of antibiotics reported by countries – and mapped against livestock densities of cattle, chickens, and pigs.  They then compared that data with hundreds of local studies and reports of antimicrobial resistance, referring to major indicator bacteria, like E coli, Staphylococcus, Campylobacter, and salmonella. Combined together, they yield a profile of the leading AMR hotspots across the world: The resulting “heat maps” demonstrate a clear correlation between drug overuse and drug resistance by mutating pathogens.  

Their research relies upon hundreds of local studies on farms, markets and slaughterhouses, routinely done “by academics and veterinarians and microbiologists, who go out and look at what’s around their institute, to identify new resistant [pathogen] genes – something microbiologists like to do very much.  But such studies typically are scattered across the literature and published in small journals that “hardly get any exposure.” Brought together, however, they provide powerful insights.

“One of the cool things is that you can zoom in to see where the problem is inside a country as well as the main regions identified as having high resistance,” says Van Boeckel. 

Not surprisingly, most of the AMR hotspots are largely in the same places that have the largest use of antibiotics, per kilogram per meat, such as South India, South and Northeast China, and some parts of Latin America.

Trends in Asia are particularly worrisome since antimicrobial use for livestock and poultry is slated to grow even more across Asia in this decade, and represent two-thirds of the world’s veterinary consumption of antimicrobials by 2030. 

Regions by region, trends in animal antimicrobial sales in LMICs largely correspond with growth in AMR hotspots.

By 2030, Asia will consume two-third’s of the world’s veterinary antibiotics  

China is the largest consumer of antibiotics in animals.

“In 2017… the world used around 90,000 tons of antimicrobials in animals – at the time China was by far the largest consumer of antibiotics in animals,” reported Van Boeckel. 

“By 2030, Asia will use more than two-thirds of the veterinary antibiotics in the world – while Africa will use only 6%. So arguably, Africa has little responsibility for the state of resistance and AMR today,” he said.  “And in Europe and North America, we’ve had fairly high levels of antibiotic use over the last 20 years, but they are slowly declining, thanks to increased awareness about the need for stewardship in our farms.” 

With the notable exception of Brazil, most of the 40 countries reporting systematically on veterinary antimicrobial use are major meat exporters – “which likely want to keep a good image in the securities export market,” said Van Boeckel.

But among countries producing meat for mostly domestic consumption systematic national reporting is more sparse – and the researchers had to gather their data from a hybrid of commercial and research study sources. 

Low- and middle-income countries failing to track AMR trends

But perhaps even more significantly, low- and middle-income countries are generally not tracking trends in AMR trends in livestock in any systematic manner, Van Boeckel pointed out. 

Such surveillance is critical since the first sign of superbugs is likely to occur in and around animals, not people, given their role of animals as the world’s biggest antibiotic consumers. 

“In Europe, we have systematic surveillance systems with a compelling metric for AMR for two to three decades, and we report this information at the national level,” Van Boeckel said.  That surveillance eventually helped drive a wave of awareness and ultimately a European Union ban on the use of health- promoting antibiotics in 2006. 

Now, as the bulk of veterinary antibiotic use has shifted to low and middle income countries, “that’s really where the attention should be in the future.”   

However, out of 135 low and middle income countries that the team explored, only one, Colombia, had a government-run surveillance system that generates public data.

Pigs and chickens incubating more superbugs than cattle

Superbugs increased almost 200% more in pigs and chickens than cattle.

The team also has mapped trends by species. And that shows resistant pathogens increasing at a faster rate amongst pigs and chickens – whereas the prevalence of AMR amongst cattle is rising more moderately.  

“Our goal for the next step is going to be to use that information to produce a global map of resistance levels across limited income countries. So concretely, we want to move from content information to continue continuous coverage of resistance level to do what some would call a heat map,” he said. 

Meat-heavier diets and exports in Asia and Americas driving trends  

Meat-heavy diets fuel AMR.

One key factor driving trends are the financial incentives offered by animal health companies to veterinarians – which reap a hefty profit from selling more and more drugs to farmers with little knowledge of the products. They do so with minimal interference from governments, not only in Asia but also in some developed countries too, Van Boeckel says.  

Another is the growing, and seemingly unquenchable hunger for more animal products in emerging economies as well as developed countries, which is the more fundamental driver of soaring livestock production, which in turn leads to more veterinary antibiotic use – and therefore AMR.  

Van Boeckel compared the daily, per capita consumption of meat in Mali, which averages less than 27 grams a day, to that of China, at 136 grams, and Australia, at a whopping 260 grams. Those contrasts are captured in a series of photos that reflect a family’s typical weekly household food consumption across the three continents. 

The photos reflect not only more meat, but also heavier consumption of ultra-processed foods and sugary drinks in emerging economies and developed ones – dietary trends that are simultaneously harming people’s health, the planet – and driving AMR.  

Policy solutions – a user fee for veterinary antibiotics? 

Targets to reduce antimicrobial use include regulation and meat reduction.

Along with better tracking, global agencies need to be thinking about the kinds of policy solutions that would really bring the AMR under control, he stresses.  His team mapped out several key possibilities to proejct their results:  

  • Regulatory action to reduce the use of antibiotics in livestock worldwide to 50 milligrams per kilogram of meat produced, roughly the European median, would reduce veterinary antibiotic use by 64%; 
  • Regulatory action among only OECD countries and China to do the same – would lead to an almost equally sharp reduction in veterinary antibiotics of 60%; 
  • Consumer action to reduce meat consumption to just 60 grams a day – “about the equivalent of one Big Mac” – also would reduce antibiotic use in livestock by some 66%; 

“In other words, maybe we shouldn’t undermine the development of certain countries through livestock farming, as long as we have the OECD and China in the deal. We can make a significant difference,” says Van Boeckel. 

Yet another solution is to impose stiffer taxes, or user fees on antibiotics, which would in turn curb the incentives that now exist to farmers to purchase them at all – particularly when alternatives exist such as better sanitation practices, including more vaccination against preventible diseases.     

In UN – One Health rhetoric but little real action  

Jorge Matheu Alvarez of WHO discusses challenges of more harmonized surveillance of human and animal antimicrobial use and AMR trends.

Such systematic global tracking of human and veterinary drug sales, and AMR trends should in fact be done by governments, and collected by the UN and its partners, Van Boeckel asserts.

But data on antimicrobial drug sales for human and animal use – and AMR trends in both populations – is not collated and reported systematically by the major UN and multilateral organizations responsible.

WHO, through its Global Antimicrobial Resistance and Surveillance System (GLASS), is trying improve surveillance of AMR in association with drugs used for human health, said Jorge Matheu Alvarez of WHO, who also appeared at the session. But tracking antibiotic consumption in animals or AMR in livestock isn’t really WHO’s job, he said.     

OIE tracks some data on veterinary use of antimicrobials, but that data remains very partial, with only 133 countries reporting to OIE at all. Many countries that do report lack data on actual quantities of antibiotics used or sold. In addition, the data is not transparent.  Some 71% of countries that do report to OIE don’t make their data public. And therefore OIE’s data is presented only in terms of aggregate global quantities, rather by region or country.  No data on AMR trends in animals is published by the member state organization. 

WHO, FAO, OIE and the World Animal Health Organization have recently launched a new One Health collaboration together with the UN Environment Programme.  Both FAO and OIE have included antimicrobial stewardship in the animal sector in their global action plans, Alvarez noted saying: “we are making progress in the collaboration in these One Health areas.”

Alvarez says FAO, OIE and WHO will soon begin placing the surveillance data they do collect on a single platform, called the Tripartite Integrated Surveillance System on AMR (TISSA).

“Here we will host the One Health information collected by the different organizations on AMR, antimicrobial consumption and use of antimicrobials,” he told Health Policy Watch.

But animal and human data thus collected won’t likely be reported and presented in a comparable manner for some time to come, he admits, because of different data collection methods.  

Member states are highly resistant to reporting on their antibiotic drug sales and consumption – because they see it has implications for their global trade in meat, the panelists also noted.  

“We need to be clearer and provide more guidance in the animal sector,” Alvarez told the panel session.  The session was hosted by the Global Antibiotic R&D Partnership (GARDP), which aims to acccelerate the development of new antibiotic treatments for drug resistant infections and also attended by the Foundation for Innovative New Diagnostics (FIND), which is ramping up the development and deployment of infection tests to reduce unecessary use of antibiotics in humans.

Says Van Boeckel, “I’ve been in this field for about ten years, and I thought something would have happened by now. I’ve been expecting a globally harmonized AMR surveillance system by the FAO and OIE that reports that data. And I can only ask the question, why hasn’t that happened?  

Until those agencies, and the member states that control them, rise to the challenge, surveillance of critical AMR trends will likely remain the purview of research teams such as Van Boeckel’s.  But meanwhile, the neglect of animals’ antibiotic consumption remains just another pandemic waiting to happen, he warns:      

“If we want to inform policy in the short term, we need an alternative systematic surveillance system for LMICs, where we’ve seen that conditions may unfortunately be the worst, when it comes to development of resistance, in the coming decades.”

Updated on  5 May, 2022

Image Credits: Thomas Van Boekel, Health Policy Watch , Van Boeckel et al, ETH Zurich, Tiseo et al 2020, Antibiotics .